Literature DB >> 11041450

Cyclin D1 overexpression in thyroid carcinomas: relation with clinico-pathological parameters, retinoblastoma gene product, and Ki67 labeling index.

F Basolo1, M A Caligo, A Pinchera, F Fedeli, A Baldanzi, P Miccoli, P Iacconi, G Fontanini, F Pacini.   

Abstract

Cyclin D1 is a G1 cyclin participating in the control of cell cycle progression through interaction with the retinoblastoma gene product (pRB). The overexpression of positive regulators (such as cyclin D1) has been reported in a variety of neoplasms, but their role in thyroid tumorigenesis is yet to be established. In our series of 54 thyroid carcinomas, cyclin D1 overexpression (detected by both immunohistochemistry and by Northern blotting) was correlated with prognostic variables, proliferative activity and pRB. Cyclin D1 overexpression was observed in 35% of thyroid carcinomas with a significantly higher expression of this cyclin in neoplastic tissues than in matched normal parenchyma. In well-differentiated carcinomas, the cyclin D1 mRNA overexpression was inversely correlated with nodal status (p = 0.03), while the protein product was higher in tumors from patients less than 40 than patients over 40 years of age. Inversely, there was no significant correlation with gender and tumor status, pRB and with proliferative activity.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11041450     DOI: 10.1089/thy.2000.10.741

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  11 in total

1.  SOST silencing promotes proliferation and invasion and reduces apoptosis of retinoblastoma cells by activating Wnt/β-catenin signaling pathway.

Authors:  T Wu; L-N Wang; D-R Tang; F-Y Sun
Journal:  Gene Ther       Date:  2017-06-15       Impact factor: 5.250

2.  Low level of cyclin D1 protein expression in thyroid microcarcinomas from an autopsy series.

Authors:  Gabor Laszlo Kovacs; Eva Stelkovics; Laszlo Krenacs; Gabor Gonda; Miklos Goth; Laszlo Kovacs; Zoltan Gorombey; Erika Hubina; Istvan Szabolcs
Journal:  Endocrine       Date:  2005-02       Impact factor: 3.633

Review 3.  Occult thyroid carcinoma.

Authors:  J Boucek; J Kastner; J Skrivan; E Grosso; B Gibelli; G Giugliano; J Betka
Journal:  Acta Otorhinolaryngol Ital       Date:  2009-12       Impact factor: 2.124

4.  Cyclin D1 and p27 expression as prognostic factor in papillary carcinoma of thyroid: association with clinicopathological parameters.

Authors:  Valdi Pesutić-Pisac; Ante Punda; Ivo Gluncić; Vladimir Bedeković; Anka Pranić-Kragić; Nenad Kunac
Journal:  Croat Med J       Date:  2008-10       Impact factor: 1.351

5.  Inhibitory effect of Kangjia Pill on thyrocyte proliferation in rat goiter model.

Authors:  Yong Han; Jing Zhou; Shu-jing Yu; Bin Cui; Hai-qing Zhang; Ling Gao; Jia-jun Zhao
Journal:  Chin J Integr Med       Date:  2009-08-18       Impact factor: 1.978

Review 6.  Immunohistochemical Biomarkers in Thyroid Pathology.

Authors:  Zubair Baloch; Ozgur Mete; Sylvia L Asa
Journal:  Endocr Pathol       Date:  2018-06       Impact factor: 3.943

7.  Role of estrogen in thyroid function and growth regulation.

Authors:  Ana Paula Santin; Tania Weber Furlanetto
Journal:  J Thyroid Res       Date:  2011-05-04

8.  Genome-wide expression analysis suggests a crucial role of dysregulation of matrix metalloproteinases pathway in undifferentiated thyroid carcinoma.

Authors:  Jesús Espinal-Enríquez; Said Muñoz-Montero; Ivan Imaz-Rosshandler; Aldo Huerta-Verde; Carmen Mejía; Enrique Hernández-Lemus
Journal:  BMC Genomics       Date:  2015-03-18       Impact factor: 3.969

9.  Effects of the Smad4 C324Y mutation on thyroid cell proliferation.

Authors:  Sonia D'Inzeo; Arianna Nicolussi; Francesco Nardi; Anna Coppa
Journal:  Int J Oncol       Date:  2013-04-17       Impact factor: 5.650

10.  p53 suppresses carcinoma progression by inhibiting mTOR pathway activation.

Authors:  N Akeno; A L Miller; X Ma; K A Wikenheiser-Brokamp
Journal:  Oncogene       Date:  2014-01-27       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.